NASDAQ:HALOHalozyme Therapeutics Stock Price, Forecast & News

Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HALO stock has increased by 33.2% and is now trading at $24.27. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Halozyme Therapeutics.

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Halozyme Therapeutics.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.02. The biopharmaceutical company had revenue of $25.30 million for the quarter, compared to the consensus estimate of $42.96 million. Halozyme Therapeutics had a negative net margin of 48.75% and a negative return on equity of 48.92%. The company's revenue was down 55.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.01 EPS. View Halozyme Therapeutics' earnings history.

Halozyme Therapeutics updated its FY20 earnings guidance on Monday, May, 11th. The company provided earnings per share (EPS) guidance of $0.60-0.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.62. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $239.41 million.

8 analysts have issued 1-year price objectives for Halozyme Therapeutics' stock. Their forecasts range from $20.00 to $39.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $28.63 in the next year. This suggests a possible upside of 17.9% from the stock's current price. View analysts' price targets for Halozyme Therapeutics.

Press coverage about HALO stock has been trending very negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Halozyme Therapeutics earned a news impact score of -3.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutHalozyme Therapeutics.

Halozyme Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 15,480,000 shares, an increase of 9.4% from the April 30th total of 14,150,000 shares. Based on an average daily trading volume, of 1,780,000 shares, the short-interest ratio is presently 8.7 days. Approximately 12.0% of the shares of the company are short sold. View Halozyme Therapeutics' Current Options Chain.

Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Gilead Sciences (GILD), NIC (EGOV), Micron Technology (MU), Allergan (AGN) and Aegean Marine Petroleum Network (ANW).

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Halozyme Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.80%), Third Security LLC (5.10%), William Blair Investment Management LLC (4.75%), JPMorgan Chase & Co. (3.53%), State Street Corp (3.16%) and Invesco Ltd. (2.71%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros, Kenneth J Kelley, Michael J Labarre and Randal J Kirk. View institutional ownership trends for Halozyme Therapeutics.

HALO stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Invesco Ltd., Two Sigma Investments LP, Nuveen Asset Management LLC, Federated Hermes Inc., Deutsche Bank AG, DeepCurrents Investment Group LLC, and State Street Corp. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Dimitrios Chondros, and Michael J Labarre. View insider buying and selling activity for Halozyme Therapeutics.

HALO stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Eagle Asset Management Inc., Two Sigma Advisers LP, Castleark Management LLC, Fuller & Thaler Asset Management Inc., Portolan Capital Management LLC, Penn Capital Management Co. Inc., and JPMorgan Chase & Co.. View insider buying and selling activity for Halozyme Therapeutics.

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HALO stock can currently be purchased for approximately $24.27.

Halozyme Therapeutics has a market capitalization of $3.30 billion and generates $195.99 million in revenue each year. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.

The official website for Halozyme Therapeutics is www.halozyme.com.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]